Amarin Corporation PLC (NASDAQ:AMRN) now has FDA approval for its triglyceride drug, Vascepa, and it is ready to take it to market early in 2013. But the stock hasn’t exactly spiked since the approval, and only today has the stock made a …
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of …
NEW YORK, Nov. 8, 2017 /PRNewswire/ -- If you want a Stock Review on AMRN, ENDP, IONS, or TEVA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pharmaceutical manufacturers …
Even more importantly, this was an $8 and $9 stock the prior week. It seems hard to get excited here after such a big price drop this past week, but those calls were made that still implied high upside. On Thursday, Amarin Corp. PLC …
On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Amarin (NASDAQ: AMRN) is a “speculative …
AMRN stock sells at 6.3 x Sales - which is very rich valuation IMO with virtually no growth in the EPA market. Odds of Reduce-IT success are EXTREMELY LOW. If Reduce IT fails (& most likely it will fail) the stock can start trading at 3 x …
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, will visit the Nasdaq MarketSite in Times Square. In …